MDNA11

Interleukin-2 beta-selective agonist · Medicenna Therapeutics, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for MDNA11, covering 2025-07-09 to 2025-07-09. Get the full timeline:

Most recent: Clinical Trial Update: A Beta-only IL-2 ImmunoTherapY Study [Phase 1, Phase 2]